INFI
Price:
$0.008
Market Cap:
$726.09K
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, ...[Read more]
Industry
Biotechnology
IPO Date
2000-07-28
Stock Exchange
NASDAQ
Ticker
INFI
According to Infinity Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -3433.02%. This represents a change of -6726.51% compared to the average of 51.81% of the last 4 quarters.
The mean historical ROE of Infinity Pharmaceuticals, Inc. over the last ten years is -75.31%. The current -3433.02% ROE has changed 4.46% with respect to the historical average. Over the past ten years (40 quarters), INFI's ROE was at its highest in in the June 2022 quarter at 1.08%. The ROE was at its lowest in in the December 2019 quarter at -147.32%.
Average
-75.31%
Median
-49.75%
Minimum
-609.07%
Maximum
227.05%
Discovering the peaks and valleys of Infinity Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.74%
Maximum Annual ROE = 227.05%
Minimum Annual Increase = -212.79%
Minimum Annual ROE = -609.07%
Year | ROE | Change |
---|---|---|
2022 | 227.05% | -207.78% |
2021 | -210.66% | -212.79% |
2020 | 186.77% | -130.66% |
2019 | -609.07% | 2.74% |
2018 | -21.45% | -75.52% |
2017 | -87.64% | 140.06% |
2016 | -36.51% | -71.97% |
2015 | -130.26% | 1.47% |
2014 | -8.31% | -86.80% |
2013 | -62.99% | 262.08% |
The current ROE of Infinity Pharmaceuticals, Inc. (INFI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
67.72%
5-year avg
-85.47%
10-year avg
-75.31%
Infinity Pharmaceuticals, Inc.’s ROE is greater than NextCure, Inc. (-62.50%), greater than Chimerix, Inc. (-50.78%), less than Eledon Pharmaceuticals, Inc. (21.51%), less than Kiromic BioPharma, Inc. (327.18%), less than Neoleukin Therapeutics, Inc. (-8.54%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Instil Bio, Inc. (-37.44%), greater than Nuvation Bio Inc. (-108.68%), greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), less than Edgewise Therapeutics, Inc. (-26.83%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Trevi Therapeutics, Inc. (-63.30%), greater than SQZ Biotechnologies Company (-305.92%), greater than Protara Therapeutics, Inc. (-55.96%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), greater than Aditxt, Inc. (-431.38%), greater than NeuroBo Pharmaceuticals, Inc. (-189.12%), greater than Dermata Therapeutics, Inc. (-247.40%), greater than Unicycive Therapeutics, Inc. (-374.14%), greater than Revelation Biosciences, Inc. (-311.33%),
Company | ROE | Market cap |
---|---|---|
-62.50% | $24.31M | |
-50.78% | $300.39M | |
21.51% | $255.09M | |
327.18% | $1.47M | |
-8.54% | $8.20M | |
-41.34% | $83.74M | |
-121.46% | $93.56M | |
-37.44% | $142.85M | |
-108.68% | $949.12M | |
-104.85% | $71.47M | |
-64.55% | $57.32M | |
-42.26% | $726.61M | |
-42.45% | $273.18M | |
-26.83% | $2.80B | |
-178.68% | $11.28M | |
-63.30% | $357.46M | |
-305.92% | $12.83M | |
-55.96% | $177.43M | |
-237.65% | $109.72K | |
-431.38% | $2.62M | |
-189.12% | $20.33M | |
-247.40% | $2.73M | |
-374.14% | $69.56M | |
-311.33% | $2.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Infinity Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Infinity Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Infinity Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Infinity Pharmaceuticals, Inc. (INFI)?
What is the highest ROE for Infinity Pharmaceuticals, Inc. (INFI)?
What is the 3-year average ROE for Infinity Pharmaceuticals, Inc. (INFI)?
What is the 5-year average ROE for Infinity Pharmaceuticals, Inc. (INFI)?
How does the current ROE for Infinity Pharmaceuticals, Inc. (INFI) compare to its historical average?